According to FirstWord Pharma, Onchilles has raised $25 million in a series A1 round to move its lead ELANE-target injectable, N17350, through clinical proof-of-concept studies. Onchilles also simultaneously published preclinical data in Cell Reports Medicine demonstrating that N17350 led to durable responses across 30 cancer cell lines.

The raise brings Onchilles' total series A funding to $40 million. Several new investors participated in the round, including Invivium Capital, Kennedy Lewis Investment Management and UCM Ventures, as well as existing investors LYZZ Capital Advisors and Lincoln Park Capital Fund.